Loading…
Acurx Pharmaceuticals, Inc. is projected to rise to $1.51 by 2027, a +1% move from its current price of $1.50. ACXP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.44 | $1.50 | $1.57 | +0.01% |
| Jul 14 | $1.41 | $1.50 | $1.60 | +0.02% |
| Jul 15 | $1.39 | $1.50 | $1.62 | +0.04% |
| Jul 16 | $1.38 | $1.50 | $1.64 | +0.05% |
| Jul 17 | $1.36 | $1.50 | $1.66 | +0.06% |
| Jul 18 | $1.35 | $1.50 | $1.67 | +0.07% |
| Jul 19 | $1.34 | $1.50 | $1.69 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.34 | $1.50 | $1.69 | +0.09% |
| Week 2 | $1.28 | $1.50 | $1.77 | +0.17% |
| Week 3 | $1.23 | $1.50 | $1.84 | +0.26% |
| Week 4 | $1.19 | $1.51 | $1.90 | +0.35% |
| Week 5 | $1.16 | $1.51 | $1.95 | +0.44% |
| Week 6 | $1.14 | $1.51 | $2.00 | +0.52% |
| Week 7 | $1.11 | $1.51 | $2.05 | +0.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing antibiotics to treat bacterial infections in the United States.
Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme and is in Phase 2b clinical trial to treat patients with Clostridium difficile infections.
The company also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc.
was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP currently trades at $1.45 and has a market capitalization of $6.23M, ranking 5270 among listed assets.
The near-term outlook shows a flat to modestly evolving price path, with 2026 average price of $1.45 and 0% ROI, followed by a gradual uptick to 2027 average $1.47 (1.2% ROI) and a dip in 2028 (avg $1.43, -1.3% ROI) and 2029 (avg $1.32, -9% ROI).
Longer-term forecasts indicate a shift to higher price levels, with 2030 average $1.27 (-12.6% ROI) and 2032 average $1.68 (15.9% ROI). The outlook strengthens into 2033 with average $1.87 and 29% ROI, continuing through 2034 at $1.80 (24.2% ROI) and 2035 at $1.77 (22.1% ROI). By 2040, the average price is projected at $2.65 with an 82.9% ROI, and by 2050 the average is $3.09 with a 113.2% ROI.
A major floor 34.2% below — a decisive break under it would weaken the trend.
The nearest floor, 9.3% below — buyers have tended to step in here.
The nearest ceiling, 32.7% above — a clean break opens room to run.
A major ceiling 342.0% above — clearing it would confirm fresh momentum.
Key ACXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.47 | Buy | $1.48 | Buy |
| MA 10 | $1.52 | Sell | $1.50 | Buy |
| MA 20 | $1.52 | Sell | $1.55 | Sell |
| MA 50 | $1.77 | Sell | $1.82 | Sell |
| MA 100 | $2.37 | Sell | $2.30 | Sell |
| MA 200 | $3.22 | Sell | $4.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.88 | Neutral |
| Stoch RSI (14) | 78.85 | Neutral |
| CCI (20) | -25.68 | Neutral |
| Williams %R (14) | -56.25 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 5.63 | Buy |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 43.75 | Neutral |
| TRIX (15) | -0.88 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 44.37 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 1.40 | Buy |
| ADX (14) | 24.28 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture for ACXP is NEUTRAL.
The RSI(14) is 40, indicating neutral momentum and room to move without being overbought or oversold.
The 50-day simple moving average sits at $1.80 and the 200-day simple moving average sits at $3.26, highlighting a closer near-term level around $1.80 but a longer-term average above $3.00. Support is listed at $1.42 and resistance at $1.99. The 30-day trading range spans from $1.10 to $1.92.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.50 | $1.94 | 0% | Neutral | |
| $1.14 | $1.51 | $2.16 | +1% | Neutral | |
| $1.05 | $1.47 | $2.22 | -2% | Neutral | |
| $0.945 | $1.37 | $2.16 | -8% | Neutral | |
| $0.8609 | $1.30 | $2.12 | -14% | Neutral | |
| $0.8468 | $1.32 | $2.22 | -12% | Neutral | |
| $1.08 | $1.74 | $3.01 | +16% | Neutral | |
| $1.16 | $1.93 | $3.41 | +28% | Bullish | |
| $1.09 | $1.86 | $3.37 | +24% | Bullish | |
| $1.05 | $1.84 | $3.39 | +23% | Bullish | |
| $1.37 | $2.74 | $5.51 | +83% | Bullish | |
| $1.44 | $3.20 | $7.24 | +113% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.35 | $1.50 | $1.89 | +0.00% |
| August 2026 | $1.32 | $1.58 | $1.96 | +5.22% |
| September 2026 | $1.25 | $1.52 | $1.92 | -3.87% |
| October 2026 | $1.24 | $1.52 | $1.96 | +0.47% |
| November 2026 | $1.26 | $1.55 | $2.02 | +1.81% |
| December 2026 | $1.19 | $1.48 | $1.94 | -4.78% |
Click any year to see its month-by-month ACXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ACXP is projected to trade between $1.35 and $1.94, averaging $1.50 — a potential gain of 0% from today's $1.50. A consolidation phase looks the most probable path here.
Acurx Pharmaceuticals, Inc.'s 2027 outlook centres on $1.51, within a $1.14 to $2.16 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2028, ACXP could reach as high as $2.22, with a base case around $1.47 and support toward $1.05 — roughly -2% from $1.50. A consolidation phase looks the most probable path here.
Expect ACXP to range from $0.945 to $2.16 through 2029. The $1.37 average target implies a -8% move from current prices. That is -7% versus the projected 2028 average. Price action looks broadly range-bound.
The ACXP price prediction for 2030 points to an average of $1.30 (low $0.8609, high $2.12) — a potential decline of -14% on today's $1.50. A consolidation phase looks the most probable path here.
In 2031, ACXP is projected to trade between $0.8468 and $2.22, averaging $1.32 — a potential decline of -12% from today's $1.50. That is up +2% on the projected 2030 average. Price action looks broadly range-bound.
Acurx Pharmaceuticals, Inc.'s 2032 outlook centres on $1.74, within a $1.08 to $3.01 range. That is up +32% on the projected 2031 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, ACXP could reach as high as $3.41, with a base case around $1.93 and support toward $1.16 — roughly +28% from $1.50. Momentum favours further upside here.
Expect ACXP to range from $1.09 to $3.37 through 2034. The $1.86 average target implies a +24% move from current prices. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The ACXP price prediction for 2035 points to an average of $1.84 (low $1.05, high $3.39) — a potential gain of +23% on today's $1.50. Momentum favours further upside here.
In 2040, ACXP is projected to trade between $1.37 and $5.51, averaging $2.74 — a potential gain of +83% from today's $1.50. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Acurx Pharmaceuticals, Inc.'s 2050 outlook centres on $3.20, within a $1.44 to $7.24 range. That is up +17% on the projected 2040 average. That marks a +113% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ACXP today (≈ 666.666667 ACXP) could be worth
$2,134.1
+$1,134.1 (+113%) by 2050 · US Dollar
Based on the average projected ACXP price of $3.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACXPwould be worth at today's price.
$1,000 invested in ACXP on Jul 10, 2025 (≈ 100.200405 ACXP) would be worth
$150.3
-$849.7 (-85.0%) today · 0.15× · US Dollar
Based on a ACXP entry price of $9.98 vs. today's $1.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.6 | $937.5 | -6.3% |
| 1 month ago | $1.6 | $937.5 | -6.3% |
| 3 months ago | $2.61 | $574.71 | -42.5% |
| 6 months ago | $2.78 | $539.57 | -46.0% |
| 1 year ago | $9.98 | $150.3 | -85.0% |
| All time (5.0y) ago | $116.4 | $12.89 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACXP forecast.
Our base-case forecast reaches $3.00 around 2050.
Implied market cap at $3.00: $12.89M
The multi-year forecast shows a path from near-term flat/negative momentum to medium- and longer-term upside. In 2030 the average price is $1.27 with a -12.6% ROI, followed by 2032 at $1.68 with a 15.9% ROI and 2033 at $1.87 with a 29% ROI. 2034 and 2035 carry positive returns of 24.2% and 22.1% respectively, with averages of $1.80 and $1.77.
The outlook turns notably bullish by 2040, with an average of $2.65 and an 82.9% ROI, and extends to 2050 with an average of $3.09 and a 113.2% ROI. In the forecast, the maximum prices rise to $3.27 in 2033, $3.22 in 2034, $3.23 in 2035, $5.26 in 2040, and $6.89 in 2050, while the minimums dip to $0.8495 in 2030 and $0.8393 in 2031. These are estimates and not guarantees, and actual results may differ depending on clinical, regulatory, and market developments.
Tap a question to reveal the answer.
2030 – Min $0.8495, Avg $1.27, Max $2.05; ROI -12.6%; Sentiment NEUTRAL.
The forecast shows potential upside over the long term with 2040 Avg $2.65 and 2050 Avg $3.09 with ROIs of 82.9% and 113.2%, respectively. Near-term years (2029–2031) show negative ROIs, so outcomes are uncertain and not guaranteed.
Yes. The forecast lists a 2030 max of $2.05 and a 2033 max of $3.27, with higher maxima later at $5.26 (2040) and $6.89 (2050), indicating possible movement above $2 in multiple years.
Current price is $1.45 and market capitalization is $6.23M.
2040 – Avg $2.65, Min $1.35, Max $5.26; ROI 82.9%; Sentiment BULLISH.
Acurx Pharmaceuticals, Inc. Community Discussion
0Share your Acurx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.